Heard on the Street: Company touts vaccine treatments
TapImmune Inc.,a Seattle-based company with ties to Mayo Clinic, is tooting its own horn this week about its advances in vaccine technologies for the treatment of cancer and infectious disease.
It's presenting at several conferences this week in New York, it said in a news release.
Peptides expressed in TapImmune's Polystart technology killed targeted human cells, showing its potential for use inurgently needed vaccines for emerging diseases like MERS and others, the release said.
"Small animal studies with a peptide based vaccine for prevention of smallpox have been very encouraging and indicate commercial product potential," the release says. The studies were done at the Mayo Clinic in Rochester.
TapImmune believes that these platforms could substantially improve many vaccines in development and currently on the market, it said.
In addition, TapImmune is developing a new HER2/neu breast cancer vaccine technology, with data from the phase 1 trial coming soon. It has other announcements coming for four other product candidates, it said, with two of them finishing phase 1 studies at Mayo Clinic.
TapImmune CEO Glynn Wilson commented, "We are extremely pleased with the progress we have made this year and the Company's fundamentals have never been stronger."
SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, recently announced that it has initiated coverage on TapImmune.
"TapImmune's breast cancer vaccine is applicable to over 50 percent of the population. The vaccine is not limited to breast cancer, as Her2/neu is a target for the vaccine in both colorectal and ovarian cancer, where there are very few therapeutic options," commented Ajay Tandon, CEO of SeeThruEquity. "We look forward to following the company's development as it addresses this market opportunity. We are initiating coverage with a price target of $6.97 per share." — Mike Klein